118 related articles for article (PubMed ID: 29807113)
1. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.
Kalu NN; Mazumdar T; Peng S; Tong P; Shen L; Wang J; Banerjee U; Myers JN; Pickering CR; Brunell D; Stephan CC; Johnson FM
Cancer Lett; 2018 Sep; 431():64-72. PubMed ID: 29807113
[TBL] [Abstract][Full Text] [Related]
2. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
3. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.
Biktasova A; Hajek M; Sewell A; Gary C; Bellinger G; Deshpande HA; Bhatia A; Burtness B; Judson B; Mehra S; Yarbrough WG; Issaeva N
Clin Cancer Res; 2017 Dec; 23(23):7276-7287. PubMed ID: 28916527
[No Abstract] [Full Text] [Related]
4. Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers.
Ghosh S; Mazumdar T; Xu W; Powell RT; Stephan C; Shen L; Shah PA; Pickering CR; Myers JN; Wang J; Frederick MJ; Johnson FM
Clin Cancer Res; 2022 Oct; 28(20):4479-4493. PubMed ID: 35972731
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
Shaikh MH; Idris A; Johnson NW; Fallaha S; Clarke DTW; Martin D; Morgan IM; Gabrielli B; McMillan NAJ
Oral Oncol; 2018 Nov; 86():105-112. PubMed ID: 30409290
[TBL] [Abstract][Full Text] [Related]
6. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
Kramer B; Kneissle M; Birk R; Rotter N; Aderhold C
Anticancer Res; 2018 May; 38(5):2723-2731. PubMed ID: 29715092
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors.
Martin D; Fallaha S; Proctor M; Stevenson A; Perrin L; McMillan N; Gabrielli B
Mol Cancer Ther; 2017 Sep; 16(9):1934-1941. PubMed ID: 28522591
[TBL] [Abstract][Full Text] [Related]
9. The effect of danusertib, an Aurora kinase inhibitor, onto the cytotoxicity, cell cycle and apoptosis in pancreatic ductal adenocarcinoma cells.
Kirbiyik IA; Ozcimen AA
J Cancer Res Ther; 2021; 17(6):1419-1424. PubMed ID: 34916372
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas.
Lindsay CD; Kostiuk MA; Harris J; O'Connell DA; Seikaly H; Biron VL
Clin Epigenetics; 2017; 9():95. PubMed ID: 28878842
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.
Morris V; Rao X; Pickering C; Foo WC; Rashid A; Eterovic K; Kim T; Chen K; Wang J; Shaw K; Eng C
Mol Cancer Res; 2017 Nov; 15(11):1542-1550. PubMed ID: 28784613
[TBL] [Abstract][Full Text] [Related]
12. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
13. Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer.
Gabrielli B; Bokhari F; Ranall MV; Oo ZY; Stevenson AJ; Wang W; Murrell M; Shaikh M; Fallaha S; Clarke D; Kelly M; Sedelies K; Christensen M; McKee S; Leggatt G; Leo P; Skalamera D; Soyer HP; Gonda TJ; McMillan NA
Mol Cancer Ther; 2015 Dec; 14(12):2753-61. PubMed ID: 26516156
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
[TBL] [Abstract][Full Text] [Related]
15. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
16. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
17. Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.
Qi L; Zhang Y
Tumour Biol; 2015 Mar; 36(3):1797-802. PubMed ID: 25366143
[TBL] [Abstract][Full Text] [Related]
18. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
19. Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms.
Mertens B; Nogueira T; Stranska R; Naesens L; Andrei G; Snoeck R
Oncotarget; 2016 Jul; 7(30):47302-47318. PubMed ID: 27331622
[TBL] [Abstract][Full Text] [Related]
20. TMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylation.
Dixit R; Kemp C; Kulich S; Seethala R; Chiosea S; Ling S; Ha PK; Duvvuri U
Sci Rep; 2015 Nov; 5():16657. PubMed ID: 26563938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
